<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229371</url>
  </required_header>
  <id_info>
    <org_study_id>ADD-V-A001</org_study_id>
    <nct_id>NCT01229371</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers</brief_title>
  <official_title>Randomized, Parallel-group, Double-blind Multi-center Phase III Study to Assess the Immunogenicity and Safety of the 2010/2011-season Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers, in Elderly and Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the humoral immune response and safety of the
      parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine Inflexal V
      using two different HA antigen suppliers (AdImmune and CSL), in groups of young and elderly
      adults, using the EMA (European Medicines Agency) regulation as a guideline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to evaluate the humoral immunogenicity and safety of the
      parenteral formulation of the 2010/2011-season influenza vaccine, Inflexal V, using HA
      antigen obtained from 2 different production facilities, and to compare the immunogenicity of
      both formulations to pre-defined EMA criteria for the annual relicensing of seasonal
      influenza vaccines. The evaluation will be done in young adults and elderly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity - Geometric Mean Titer Fold Increase From Baseline</measure>
    <time_frame>3 weeks after vaccination (Day 22 ± 2 days)</time_frame>
    <description>The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA &quot;Note for guidance on harmonisation of requirements for influenza vaccines,&quot; 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity - Seroprotection Rate</measure>
    <time_frame>3 weeks after vaccination (Day 22 ± 2 days)</time_frame>
    <description>The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA &quot;Note for guidance on harmonisation of requirements for influenza vaccines,&quot; 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity - Seroconversion Rate</measure>
    <time_frame>3 weeks after vaccination (Day 22 ± 2 days)</time_frame>
    <description>The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA &quot;Note for guidance on harmonisation of requirements for influenza vaccines,&quot; 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local and Systemic Adverse Events</measure>
    <time_frame>Baseline (Day 1) and 3 weeks after vaccination (Day 22 ± 2 days)</time_frame>
    <description>Solicited local and systemic AEs, Unsolicited AEs, Tolerability and acceptability
Unsolicited AEs were collected from baseline (Day 1) to 3 weeks after vaccination (Day 22 ± 2 days).
Solicited local and systemic AEs were collected by subjects diary from Day 1 (day of vaccination) to Day 4</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Subjects ≥18 to ≤60 Years - CSL HA Antigen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group A will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects &gt;60 Years - CSL HA Antigen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group B will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects ≥18 to ≤60 Years - AdImmune HA Antigen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group C will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects &gt;60 Years - AdImmune HA Antigen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group D will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inflexal V influenza vaccine (CSL HA Antigen) 2010</intervention_name>
    <description>Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus</description>
    <arm_group_label>Subjects ≥18 to ≤60 Years - CSL HA Antigen</arm_group_label>
    <arm_group_label>Subjects &gt;60 Years - CSL HA Antigen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011</intervention_name>
    <description>Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus</description>
    <arm_group_label>Subjects ≥18 to ≤60 Years - AdImmune HA Antigen</arm_group_label>
    <arm_group_label>Subjects &gt;60 Years - AdImmune HA Antigen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female and male adults

          -  Aged ≥18 years on Day 1

          -  Written informed consent

        Exclusion Criteria:

          -  Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or
             other acute disease

          -  Acute febrile illness (≥38.0 °C)

          -  Prior vaccination with an influenza vaccine (including the H1N1 pandemic swine flu
             vaccine) in the past 330 days

          -  Known hypersensitivity to any vaccine component

          -  Previous history of a serious adverse reaction to influenza vaccine

          -  History of egg protein allergy or severe atopy

          -  Known blood coagulation disorder

          -  Chronic (longer than 14 days) administration of immunosuppressants or other
             immune-modifying drugs within 6 months before the first dose of the study vaccine,
             incl. oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent
             (inhaled or topical steroids are allowed)

          -  Known immunodeficiency (incl. leukemia, cancer, HIV seropositivity)

          -  Investigational medicinal product received in the past 3 months (90 days)

          -  Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months
             (90 days)

          -  Pregnancy or lactation

          -  Participation in another clinical trial

          -  Employee at the investigational site, or spouse and children of the investigator, or
             relative living in the same household as the investigator and/or are dependent on the
             investigator

          -  Suspected non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Seiberling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit AG</name>
      <address>
        <city>Allschwil</city>
        <zip>4123</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Research S.A. Phase I Unit</name>
      <address>
        <city>Arzo</city>
        <zip>6864</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <results_first_submitted>October 23, 2012</results_first_submitted>
  <results_first_submitted_qc>February 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2013</results_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Virus</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Immunisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Hemagglutinins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 19 October 2010 to 09 November 2010; outpatient study</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects ≥18 to ≤60 Years - AdImmune HA Antigen</title>
        </group>
        <group group_id="P2">
          <title>Subjects ≥18 to ≤60 Years - CSL HA Antigen</title>
        </group>
        <group group_id="P3">
          <title>Subjects &gt;60 Years - AdImmune HA Antigen</title>
        </group>
        <group group_id="P4">
          <title>Subjects &gt;60 Years - CSL HA Antigen</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="110"/>
                <participants group_id="P4" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="110"/>
                <participants group_id="P4" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects ≥18 to ≤60 Years - AdImmune HA Antigen</title>
        </group>
        <group group_id="B2">
          <title>Subjects ≥18 to ≤60 Years - CSL HA Antigen</title>
        </group>
        <group group_id="B3">
          <title>Subjects &gt;60 Years - AdImmune HA Antigen</title>
        </group>
        <group group_id="B4">
          <title>Subjects &gt;60 Years - CSL HA Antigen</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="110"/>
            <count group_id="B4" value="110"/>
            <count group_id="B5" value="440"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="11.18"/>
                    <measurement group_id="B2" value="39.9" spread="12.10"/>
                    <measurement group_id="B3" value="66.5" spread="5.50"/>
                    <measurement group_id="B4" value="66.4" spread="5.06"/>
                    <measurement group_id="B5" value="53.1" spread="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="110"/>
                    <measurement group_id="B5" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity - Geometric Mean Titer Fold Increase From Baseline</title>
        <description>The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA &quot;Note for guidance on harmonisation of requirements for influenza vaccines,&quot; 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT</description>
        <time_frame>3 weeks after vaccination (Day 22 ± 2 days)</time_frame>
        <population>Intent-to-treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects ≥18 to ≤60 Years - AdImmune HA Antigen</title>
          </group>
          <group group_id="O2">
            <title>Subjects ≥18 to ≤60 Years - CSL HA Antigen</title>
          </group>
          <group group_id="O3">
            <title>Subjects &gt;60 Years - AdImmune HA Antigen</title>
          </group>
          <group group_id="O4">
            <title>Subjects &gt;60 Years - CSL HA Antigen</title>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Geometric Mean Titer Fold Increase From Baseline</title>
          <description>The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA &quot;Note for guidance on harmonisation of requirements for influenza vaccines,&quot; 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT</description>
          <population>Intent-to-treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
          <units>GMT fold increase</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT fold increase from baseline: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.8" upper_limit="4.3"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.3" upper_limit="5.0"/>
                    <measurement group_id="O3" value="4.5" lower_limit="3.6" upper_limit="5.7"/>
                    <measurement group_id="O4" value="3.4" lower_limit="2.8" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT fold increase from baseline: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2.1" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2.1" upper_limit="2.9"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.8" upper_limit="2.6"/>
                    <measurement group_id="O4" value="1.9" lower_limit="1.5" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT fold increase from baseline: B-strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="2.6" upper_limit="3.8"/>
                    <measurement group_id="O2" value="3.1" lower_limit="2.6" upper_limit="3.7"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.7" upper_limit="2.2"/>
                    <measurement group_id="O4" value="2.1" lower_limit="1.8" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local and Systemic Adverse Events</title>
        <description>Solicited local and systemic AEs, Unsolicited AEs, Tolerability and acceptability
Unsolicited AEs were collected from baseline (Day 1) to 3 weeks after vaccination (Day 22 ± 2 days).
Solicited local and systemic AEs were collected by subjects diary from Day 1 (day of vaccination) to Day 4</description>
        <time_frame>Baseline (Day 1) and 3 weeks after vaccination (Day 22 ± 2 days)</time_frame>
        <population>Safety population, all vaccinated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects ≥18 to ≤60 Years - AdImmune HA Antigen</title>
          </group>
          <group group_id="O2">
            <title>Subjects ≥18 to ≤60 Years - CSL HA Antigen</title>
          </group>
          <group group_id="O3">
            <title>Subjects &gt;60 Years - AdImmune HA Antigen</title>
          </group>
          <group group_id="O4">
            <title>Subjects &gt;60 Years - CSL HA Antigen</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local and Systemic Adverse Events</title>
          <description>Solicited local and systemic AEs, Unsolicited AEs, Tolerability and acceptability
Unsolicited AEs were collected from baseline (Day 1) to 3 weeks after vaccination (Day 22 ± 2 days).
Solicited local and systemic AEs were collected by subjects diary from Day 1 (day of vaccination) to Day 4</description>
          <population>Safety population, all vaccinated subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs (unsolicited and solicited)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity - Seroprotection Rate</title>
        <description>The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA &quot;Note for guidance on harmonisation of requirements for influenza vaccines,&quot; 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT</description>
        <time_frame>3 weeks after vaccination (Day 22 ± 2 days)</time_frame>
        <population>Intent-to-treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects ≥18 to ≤60 Years - AdImmune HA Antigen</title>
          </group>
          <group group_id="O2">
            <title>Subjects ≥18 to ≤60 Years - CSL HA Antigen</title>
          </group>
          <group group_id="O3">
            <title>Subjects &gt;60 Years - AdImmune HA Antigen</title>
          </group>
          <group group_id="O4">
            <title>Subjects &gt;60 Years - CSL HA Antigen</title>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Seroprotection Rate</title>
          <description>The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA &quot;Note for guidance on harmonisation of requirements for influenza vaccines,&quot; 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT</description>
          <population>Intent-to-treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
          <units>percentage subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of subjects seroprotected: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" lower_limit="95.0" upper_limit="100"/>
                    <measurement group_id="O2" value="98.2" lower_limit="93.6" upper_limit="99.8"/>
                    <measurement group_id="O3" value="92.7" lower_limit="82.8" upper_limit="96.8"/>
                    <measurement group_id="O4" value="90.0" lower_limit="82.8" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroprotected: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" lower_limit="95.0" upper_limit="100"/>
                    <measurement group_id="O2" value="99.1" lower_limit="95.0" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="96.7" upper_limit="100"/>
                    <measurement group_id="O4" value="99.1" lower_limit="95.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroprotected: B-strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="90.9" upper_limit="99.0"/>
                    <measurement group_id="O2" value="97.3" lower_limit="92.2" upper_limit="99.4"/>
                    <measurement group_id="O3" value="85.5" lower_limit="77.5" upper_limit="91.5"/>
                    <measurement group_id="O4" value="86.4" lower_limit="78.5" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity - Seroconversion Rate</title>
        <description>The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA &quot;Note for guidance on harmonisation of requirements for influenza vaccines,&quot; 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT</description>
        <time_frame>3 weeks after vaccination (Day 22 ± 2 days)</time_frame>
        <population>Intent-to-treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects ≥18 to ≤60 Years - AdImmune HA Antigen</title>
          </group>
          <group group_id="O2">
            <title>Subjects ≥18 to ≤60 Years - CSL HA Antigen</title>
          </group>
          <group group_id="O3">
            <title>Subjects &gt;60 Years - AdImmune HA Antigen</title>
          </group>
          <group group_id="O4">
            <title>Subjects &gt;60 Years - CSL HA Antigen</title>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Seroconversion Rate</title>
          <description>The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA &quot;Note for guidance on harmonisation of requirements for influenza vaccines,&quot; 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT</description>
          <population>Intent-to-treat population, vaccinated subjects with available pre- and post-vaccination titers</population>
          <units>percentage subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of subjects seroprotected: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" lower_limit="35.4" upper_limit="54.8"/>
                    <measurement group_id="O2" value="52.7" lower_limit="43.0" upper_limit="62.3"/>
                    <measurement group_id="O3" value="54.5" lower_limit="44.8" upper_limit="64.1"/>
                    <measurement group_id="O4" value="43.6" lower_limit="34.2" upper_limit="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroprotected: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="19.4" upper_limit="36.9"/>
                    <measurement group_id="O2" value="29.1" lower_limit="20.8" upper_limit="38.5"/>
                    <measurement group_id="O3" value="25.5" lower_limit="17.6" upper_limit="34.6"/>
                    <measurement group_id="O4" value="17.3" lower_limit="10.7" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of subjects seroprotected: B-strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" lower_limit="31.1" upper_limit="50.2"/>
                    <measurement group_id="O2" value="44.5" lower_limit="35.1" upper_limit="54.3"/>
                    <measurement group_id="O3" value="20.9" lower_limit="13.7" upper_limit="29.7"/>
                    <measurement group_id="O4" value="20.0" lower_limit="13.0" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subjects ≥18 to ≤60 Years - AdImmune HA Antigen</title>
        </group>
        <group group_id="E2">
          <title>Subjects ≥18 to ≤60 Years - CSL HA Antigen</title>
        </group>
        <group group_id="E3">
          <title>Subjects &gt;60 Years - AdImmune HA Antigen</title>
        </group>
        <group group_id="E4">
          <title>Subjects &gt;60 Years - CSL HA Antigen</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Haemorrhage (at the injection site)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Erythema (at the injection site)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Induration (at the injection site)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pain (at the injection site)</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="109"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="111"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="110"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period between 30 to 90 days (depending on the complexitiy of the work) from the time submitted to the sponsor for review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs Director</name_or_title>
      <organization>Crucell Switzerland AG</organization>
      <phone>+41(0)319806111</phone>
      <email>info@crucell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

